17th International Congress on Myelodysplastic Syndromes
The 17th International Congress on Myelodysplastic Syndromes 3 – 6 May 2023 Marseille, France Visit the conference website
This author has not written his bio yet.
But we are proud to say that Renee Hansen contributed 93 entries already.
The 17th International Congress on Myelodysplastic Syndromes 3 – 6 May 2023 Marseille, France Visit the conference website
View Presentation: Efficacy and Safety of Oral Decitabine/Cedazuridine (ASTX27) in the CMML Subpopulation from Phase 2 and Ascertain Phase 3 Studies Abstract: Background and aims: Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell disease characterized by persistent monocytosis with dysplastic and myeloproliferative changes in the bone marrow. Hypomethylating agents have been approved for […]
View Presentation: Randomized Phase 2 Study to Assess Safety And Efficacy of Low-Dose (LD) Oral Decitabine/Cedazuridine (ASTX727) in Lower-Risk Myelodysplastic Syndromes (LR-MDS) Patients: Interim Safety Analysis Abstract: Background and Aims: Cedazuridine (CED), a cytidine deaminase(CDA) inhibitor allows oral availability of decitabine(DEC) and 5 daily doses of the fixed-dose combination of 35 mg DEC/100 mg CED (SD) […]
View Presentation: Phase 1 Study Evaluating Low-Dose (LD) Oral Decitabine/Cedazuridine (ASTX727) In Lower-Risk Myelodysplastic Syndromes (LR-MDS) Patients Abstract: Introduction and Aims: Cedazuridine (CED), a cytidine deaminase inhibitor allows oral availability of decitabine (DEC); 5 daily doses of the fixed-dose combination of 35mg DEC/100mg CED provides equivalent exposure to an IV DEC regimen of 20mg/m2 D1-5 […]
View Presentation: Phase 2 Study of Oral Decitabine/Cedazuridine in Combination with Magrolimab for Previously Untreated Subjects with Intermediate to Very High-Risk Myelodysplastic Syndromes (MDS) Abstract: Background & Aims: Parenteral therapy using hypomethylating agents (HMAs) requires 5-7 days each month, resulting in hospital or clinic visits on a chronic basis and represents a substantial burden for […]
Acute Leukemia Forum 20 – 21 April 2023 Carlsbad, CA Visit the conference website
AACR Annual Meeting 14 – 19 April 2023 Orlando, FL Visit the conference website
Click link to view article: https://www.mdpi.com/2072-6694/15/4/1315 Abstract: The overexpression of inhibitor of apoptosis (IAP) proteins is strongly related to poor survival of women with ovarian cancer. Recurrent ovarian cancers resist apoptosis due to the dysregulation of IAP proteins. Mechanistically, Second Mitochondrial Activator of Caspases (SMAC) mimetics suppress the functions of IAP proteins to restore apoptotic […]
ASH Annual Meeting 2022 10 – 13 December 2022 New Orleans, LA visit conference website
View Presentation: Prolonged Survival in Bi-Allelic TP53-Mutated (TP53mut) MDS Subjects Treated with Oral Decitabine/Cedazuridine in the Ascertain Trial (ASTX727-02) Abstract: Introduction: TP53 mutations (TP53mut) in myelodysplastic syndrome (MDS) patients have been characterized as an independent prognostic factor for poor outcome. These patients may have similar response rates to hypomethylating agents (HMAs) but markedly diminished overall […]